BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10868832)

  • 1. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
    Hanefeld M; Bouter KP; Dickinson S; Guitard C
    Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
    Walter YH; Spratt DI; Garreffa S; McLeod JF
    Eur J Clin Pharmacol; 2000 May; 56(2):129-33. PubMed ID: 10877006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
    Hirschberg Y; Karara AH; Pietri AO; McLeod JF
    Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
    Gribble FM; Manley SE; Levy JC
    Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
    Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
    Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
    Whitelaw DC; Clark PM; Smith JM; Nattrass M
    Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
    Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
    Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
    Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
    Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.